314.72
1.35%
-4.32
Pre-market:
316.13
1.41
+0.45%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
AMGEN Inc. stock is currently priced at $314.72, with a 24-hour trading volume of 2.29M.
It has seen a -1.35% decreased in the last 24 hours and a +18.48% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $317.8 pivot point. If it approaches the $314.1 support level, significant changes may occur.
Previous Close:
$319.04
Open:
$314.63
24h Volume:
2.29M
Market Cap:
$168.83B
Revenue:
$29.53B
Net Income/Loss:
$3.76B
P/E Ratio:
22.37
EPS:
14.07
Net Cash Flow:
$7.10B
1W Performance:
+0.59%
1M Performance:
+18.48%
6M Performance:
+17.00%
1Y Performance:
+38.11%
AMGEN Inc. Stock (AMGN) Company Profile
Name
AMGEN Inc.
Sector
Industry
Phone
805-447-1000
Address
One Amgen Center Drive, Thousand Oaks, CA
AMGEN Inc. Stock (AMGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-28-24 | Resumed | Raymond James | Mkt Perform |
Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-09-23 | Initiated | Deutsche Bank | Hold |
Nov-02-23 | Upgrade | Truist | Hold → Buy |
Oct-20-23 | Resumed | JP Morgan | Neutral |
Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
Oct-11-23 | Resumed | BofA Securities | Neutral |
Sep-06-23 | Initiated | HSBC Securities | Buy |
Apr-24-23 | Reiterated | Oppenheimer | Outperform |
Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Feb-13-23 | Reiterated | Truist | Buy |
Nov-18-22 | Initiated | Credit Suisse | Underperform |
Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
May-23-22 | Initiated | SVB Leerink | Mkt Perform |
Feb-09-22 | Reiterated | Barclays | Equal Weight |
Feb-09-22 | Reiterated | Jefferies | Buy |
Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
Feb-09-22 | Reiterated | Oppenheimer | Outperform |
Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
Dec-06-21 | Initiated | Goldman | Buy |
Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Dec-29-20 | Initiated | Daiwa Securities | Buy |
Oct-28-20 | Initiated | UBS | Neutral |
Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
Oct-12-20 | Upgrade | Truist | Hold → Buy |
Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
Oct-09-20 | Downgrade | Truist | Buy → Hold |
Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
Apr-15-20 | Resumed | Guggenheim | Neutral |
Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Feb-27-20 | Initiated | Barclays | Equal Weight |
Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
Dec-24-19 | Initiated | Raymond James | Mkt Perform |
Dec-17-19 | Resumed | Morgan Stanley | Overweight |
Nov-12-19 | Initiated | SunTrust | Buy |
Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Oct-17-19 | Resumed | BofA/Merrill | Neutral |
Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
AMGEN Inc. Stock (AMGN) Latest News
Amgen's IMDELLTRA receives FDA approval for lung cancer treatment - Pharmaceutical Technology
Pharmaceutical Technology
US FDA approves Amgen drug for small cell lung cancer - Marketscreener.com
Marketscreener.com
US FDA approves Amgen drug for small cell lung cancer - Reuters
Reuters
Amgen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
MarketWatch
Amgen Drug Wins US Approval for Type of Advanced Lung Cancer | Mint - Mint
Mint
Amgen wins FDA nod for new lung cancer therapy (NASDAQ:AMGN) - Seeking Alpha
Seeking Alpha
AMGEN Inc. Stock (AMGN) Financials Data
AMGEN Inc. (AMGN) Revenue 2024
AMGN reported a revenue (TTM) of $29.53 billion for the quarter ending March 31, 2024, a +12.76% rise year-over-year.
AMGEN Inc. (AMGN) Net Income 2024
AMGN net income (TTM) was $3.76 billion for the quarter ending March 31, 2024, a -52.47% decrease year-over-year.
AMGEN Inc. (AMGN) Cash Flow 2024
AMGN recorded a free cash flow (TTM) of $7.10 billion for the quarter ending March 31, 2024, a -5.75% decrease year-over-year.
AMGEN Inc. (AMGN) Earnings per Share 2024
AMGN earnings per share (TTM) was $7.00 for the quarter ending March 31, 2024, a -52.41% decline year-over-year.
AMGEN Inc. Stock (AMGN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Grygiel Nancy A. | SVP & CCO |
May 03 '24 |
Sale |
313.09 |
2,117 |
662,802 |
9,883 |
Grygiel Nancy A. | SVP & CCO |
Dec 04 '23 |
Sale |
273.03 |
2,096 |
572,276 |
10,874 |
Graham Jonathan P | EVP, Gen. Counsel & Secy. |
Nov 08 '23 |
Sale |
272.81 |
10,000 |
2,728,136 |
28,078 |
AMGEN INC | 10% Owner |
Sep 19 '23 |
Buy |
17.00 |
1,764,705 |
29,999,985 |
35,368,653 |
Gordon Murdo | EVP, Global Commercial Ops |
Aug 10 '23 |
Sale |
262.43 |
9,558 |
2,508,306 |
44,308 |
About AMGEN Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Cap:
|
Volume (24h):